vs
Side-by-side financial comparison of Senmiao Technology Ltd (AIHS) and Dianthus Therapeutics, Inc. (DNTH). Click either name above to swap in a different company.
Senmiao Technology Ltd is the larger business by last-quarter revenue ($358.7K vs $284.0K, roughly 1.3× Dianthus Therapeutics, Inc.). Senmiao Technology Ltd runs the higher net margin — -289.2% vs -22687.3%, a 22398.1% gap on every dollar of revenue. On growth, Senmiao Technology Ltd posted the faster year-over-year revenue change (-60.9% vs -78.6%).
Senmiao Technology Ltd is a China-based automotive service provider that operates online used car trading platforms, offers auto financing referral services, and matches after-sales support for individual consumers and small auto dealers across domestic regional markets. Its core segments include transaction facilitation, financing consulting, and other value-added services for the domestic automotive circulation sector.
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
AIHS vs DNTH — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $358.7K | $284.0K |
| Net Profit | $-1.0M | $-64.4M |
| Gross Margin | 13.8% | — |
| Operating Margin | -305.7% | -24486.3% |
| Net Margin | -289.2% | -22687.3% |
| Revenue YoY | -60.9% | -78.6% |
| Net Profit YoY | -83.5% | -126.6% |
| EPS (diluted) | $-0.29 | $-1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $358.7K | $284.0K | ||
| Q3 25 | $906.5K | $396.0K | ||
| Q2 25 | $836.0K | — | ||
| Q1 25 | $809.6K | $1.2M | ||
| Q4 24 | $917.0K | $1.3M | ||
| Q3 24 | $742.3K | $2.2M | ||
| Q2 24 | $873.8K | $1.9M | ||
| Q1 24 | $-71.5K | $874.0K |
| Q4 25 | $-1.0M | $-64.4M | ||
| Q3 25 | $-648.7K | $-36.8M | ||
| Q2 25 | $-164.4K | — | ||
| Q1 25 | $-1.8M | $-29.5M | ||
| Q4 24 | $-565.3K | $-28.4M | ||
| Q3 24 | $-711.4K | $-25.2M | ||
| Q2 24 | $-673.4K | $-17.6M | ||
| Q1 24 | $-1.4M | $-13.7M |
| Q4 25 | 13.8% | — | ||
| Q3 25 | 30.2% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 48.7% | — | ||
| Q4 24 | 11.6% | — | ||
| Q3 24 | 13.1% | — | ||
| Q2 24 | 29.0% | — | ||
| Q1 24 | 176.1% | — |
| Q4 25 | -305.7% | -24486.3% | ||
| Q3 25 | -83.6% | -10173.7% | ||
| Q2 25 | -73.1% | — | ||
| Q1 25 | -255.3% | -2852.7% | ||
| Q4 24 | -44.8% | -2406.9% | ||
| Q3 24 | -83.0% | -1376.6% | ||
| Q2 24 | -88.6% | -1191.8% | ||
| Q1 24 | 2115.7% | -2041.6% |
| Q4 25 | -289.2% | -22687.3% | ||
| Q3 25 | -71.6% | -9284.1% | ||
| Q2 25 | -19.7% | — | ||
| Q1 25 | -219.3% | -2537.5% | ||
| Q4 24 | -61.7% | -2144.8% | ||
| Q3 24 | -95.8% | -1159.0% | ||
| Q2 24 | -77.1% | -945.1% | ||
| Q1 24 | 1932.0% | -1573.0% |
| Q4 25 | $-0.29 | $-1.53 | ||
| Q3 25 | $-0.43 | $-0.97 | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $1.51 | $-0.82 | ||
| Q4 24 | $-0.54 | $-0.76 | ||
| Q3 24 | $-0.68 | $-0.74 | ||
| Q2 24 | $-0.64 | $-0.51 | ||
| Q1 24 | $-0.14 | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5M | $404.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $397.3K | $493.4M |
| Total Assets | $5.7M | $530.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.5M | $404.3M | ||
| Q3 25 | $677.0K | $402.6M | ||
| Q2 25 | $867.8K | — | ||
| Q1 25 | $701.3K | $263.2M | ||
| Q4 24 | $949.2K | $275.2M | ||
| Q3 24 | $792.0K | $281.1M | ||
| Q2 24 | $748.9K | $360.7M | ||
| Q1 24 | $737.7K | $377.0M |
| Q4 25 | $397.3K | $493.4M | ||
| Q3 25 | $-3.1M | $546.5M | ||
| Q2 25 | $-2.6M | — | ||
| Q1 25 | $-2.9M | $328.6M | ||
| Q4 24 | $-1.2M | $352.5M | ||
| Q3 24 | $-459.2K | $337.9M | ||
| Q2 24 | $159.2K | $358.2M | ||
| Q1 24 | $894.9K | $372.7M |
| Q4 25 | $5.7M | $530.9M | ||
| Q3 25 | $4.7M | $577.4M | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $5.8M | $348.6M | ||
| Q4 24 | $7.9M | $374.0M | ||
| Q3 24 | $8.6M | $354.2M | ||
| Q2 24 | $9.2M | $369.0M | ||
| Q1 24 | $9.9M | $382.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-865.6K | $-47.0M |
| Free Cash FlowOCF − Capex | — | $-47.1M |
| FCF MarginFCF / Revenue | — | -16591.9% |
| Capex IntensityCapex / Revenue | — | 48.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-132.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-865.6K | $-47.0M | ||
| Q3 25 | $-71.4K | $-30.6M | ||
| Q2 25 | $-321.2K | — | ||
| Q1 25 | $-48.1K | $-27.6M | ||
| Q4 24 | $356.1K | $-27.4M | ||
| Q3 24 | $175.6K | $-21.3M | ||
| Q2 24 | $16.8K | $-14.5M | ||
| Q1 24 | $-247.5K | $-14.9M |
| Q4 25 | — | $-47.1M | ||
| Q3 25 | — | $-30.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | $-49.3K | $-27.7M | ||
| Q4 24 | $355.3K | $-27.5M | ||
| Q3 24 | $175.6K | $-21.3M | ||
| Q2 24 | $15.6K | $-14.5M | ||
| Q1 24 | $-275.8K | $-15.0M |
| Q4 25 | — | -16591.9% | ||
| Q3 25 | — | -7717.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | -6.1% | -2377.8% | ||
| Q4 24 | 38.8% | -2072.0% | ||
| Q3 24 | 23.7% | -980.3% | ||
| Q2 24 | 1.8% | -780.7% | ||
| Q1 24 | 385.8% | -1713.2% |
| Q4 25 | — | 48.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.1% | 2.1% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.1% | 0.9% | ||
| Q1 24 | -39.6% | 3.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
